{
    "nct_id": "NCT03282461",
    "official_title": "A Phase 0 Open Label, Single-center Clinical Trial of ABY-029, an Anti-EGFR Fluorescence Imaging Agent Via Single Intravenous Injection to Subjects With Operable Head and Neck Cancer.",
    "inclusion_criteria": "1. Preoperative diagnosis of head and neck cancer.\n2. Tumor judged to be operable based on preoperative imaging studies.\n3. Valid informed consent by subject or subject's Legally Authorized Representative.\n4. Age â‰¥ 18 years old.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Pregnant women or women who are breast feeding.\n2. Patients on any experimental anti-EGFR targeted therapies, either investigational or FDA approved.",
    "miscellaneous_criteria": ""
}